Loading...

Axcella Health

Nasdaq:AXLA
Snowflake Description

Adequate balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
AXLA
Nasdaq
$177M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Axcella Health Inc., a biotechnology company, researches and develops novel multifactorial interventions to support health and address dysregulated metabolism in the United States. The last earnings update was 30 days ago. More info.


Add to Portfolio Compare Print
  • Axcella Health has significant price volatility in the past 3 months.
AXLA Share Price and Events
7 Day Returns
-2.3%
NasdaqGM:AXLA
0.9%
US Biotechs
-0.3%
US Market
1 Year Returns
-
NasdaqGM:AXLA
-10.9%
US Biotechs
3.9%
US Market
AXLA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Axcella Health (AXLA) -2.3% -23.5% - - - -
US Biotechs 0.9% -0.5% 2.5% -10.9% 7.9% 7.9%
US Market -0.3% 2.3% 2.3% 3.9% 36.7% 41.8%
1 Year Return vs Industry and Market
  • No trading data on AXLA.
  • No trading data on AXLA.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

AXLA Value

 Is Axcella Health undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Axcella Health is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Axcella Health has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Axcella Health. This is due to cash flow or dividend data being unavailable. The share price is $7.71.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Axcella Health's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Axcella Health's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:AXLA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-8.48
NasdaqGM:AXLA Share Price ** NasdaqGM (2019-07-19) in USD $7.71
United States of America Biotechs Industry PE Ratio Median Figure of 35 Publicly-Listed Biotechs Companies 19.66x
United States of America Market PE Ratio Median Figure of 3,083 Publicly-Listed Companies 17.92x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Axcella Health.

NasdaqGM:AXLA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:AXLA Share Price ÷ EPS (both in USD)

= 7.71 ÷ -8.48

-0.91x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Axcella Health is loss making, we can't compare its value to the US Biotechs industry average.
  • Axcella Health is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Axcella Health's expected growth come at a high price?
Raw Data
NasdaqGM:AXLA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.91x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
-30.7%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 26 Publicly-Listed Biotechs Companies 0.81x
United States of America Market PEG Ratio Median Figure of 2,123 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Axcella Health, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Axcella Health's assets?
Raw Data
NasdaqGM:AXLA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $-33.55
NasdaqGM:AXLA Share Price * NasdaqGM (2019-07-19) in USD $7.71
United States of America Biotechs Industry PB Ratio Median Figure of 437 Publicly-Listed Biotechs Companies 3.01x
United States of America Market PB Ratio Median Figure of 5,248 Publicly-Listed Companies 1.8x
NasdaqGM:AXLA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:AXLA Share Price ÷ Book Value per Share (both in USD)

= 7.71 ÷ -33.55

-0.23x

* Primary Listing of Axcella Health.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Axcella Health has negative assets, we can't compare the value of its assets to the US Biotechs industry average.

Next steps:

  1. Examine Axcella Health's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Axcella Health's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Biotechs industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Axcella Health's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Axcella Health has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

AXLA Future Performance

 How is Axcella Health expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-30.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Axcella Health expected to grow at an attractive rate?
  • Unable to compare Axcella Health's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Axcella Health's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Unable to compare Axcella Health's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:AXLA Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:AXLA Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts -30.7%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 23.1%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 18.6%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:AXLA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:AXLA Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 0 -183 1
2022-12-31 0 -172 1
2021-12-31 38 -135 2
2020-12-31 75 -55 -60 2
2019-12-31 0 -65 -66 2
NasdaqGM:AXLA Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 -35 -40
2018-12-31 -31 -36
2017-12-31 -27 -31

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Axcella Health is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Unable to determine if Axcella Health is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:AXLA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Axcella Health Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:AXLA Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -3.93 -3.93 -3.93 1.00
2022-12-31 -4.23 -4.23 -4.23 1.00
2021-12-31 -3.69 -2.67 -4.72 2.00
2020-12-31 -1.40 -0.51 -2.29 2.00
2019-12-31 -3.58 -3.58 -3.58 1.00
NasdaqGM:AXLA Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -8.48
2018-12-31 -7.97
2017-12-31 -7.37

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Axcella Health will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Axcella Health's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Axcella Health has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

AXLA Past Performance

  How has Axcella Health performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Axcella Health's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Axcella Health does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Axcella Health's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Axcella Health's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Axcella Health's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Axcella Health Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:AXLA Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 -39.70 9.74 27.59
2018-12-31 -36.22 8.41 25.49
2017-12-31 -31.06 6.01 22.92

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Axcella Health has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Axcella Health has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Axcella Health improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Axcella Health's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Axcella Health has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

AXLA Health

 How is Axcella Health's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Axcella Health's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Axcella Health is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Axcella Health's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Axcella Health's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 2.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Axcella Health Company Filings, last reported 3 months ago.

NasdaqGM:AXLA Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 38.14 24.62 66.77
2018-12-31 48.51 24.52 79.47
2017-12-31 22.89 19.56 46.82
  • Axcella Health's level of debt (64.6%) compared to net worth is high (greater than 40%).
  • Unable to establish if Axcella Health's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Axcella Health has sufficient cash runway for 1.9 years based on current free cash flow.
  • Axcella Health has sufficient cash runway for 1.8 years if free cash flow continues to grow at historical rates of 16.3% each year.
X
Financial health checks
We assess Axcella Health's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Axcella Health has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

AXLA Dividends

 What is Axcella Health's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Axcella Health dividends. Estimated to be 0% next year.
If you bought $2,000 of Axcella Health shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Axcella Health's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Axcella Health's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:AXLA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 18 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2017 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:AXLA Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Axcella Health has not reported any payouts.
  • Unable to verify if Axcella Health's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Axcella Health's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Axcella Health has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Axcella Health's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Axcella Health's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Axcella Health afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Axcella Health has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

AXLA Management

 What is the CEO of Axcella Health's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Bill Hinshaw
AGE 50
TENURE AS CEO 1.1 years
CEO Bio

Mr. William Hinshaw, also known as Bill, has been President, Chief Executive Officer and Director of Axcella Health Inc. since June 2018. Prior to this role, Mr. Hinshaw held a number of leadership positions of increasing responsibility and expanding global scope at Novartis, including Head of the NCE (Northern and Central Europe) Region for Novartis Oncology, GEM (Group Emerging Markets), as Head of the Hematology Business Franchise, and Global Head of Infectious Disease and Transplantation (IDTI). Before joining Novartis, he worked at the former Schering Plough Corporation where he held a series of commercial roles, including the Head of US Oncology. Mr. Hinshaw holds a B.S. in Molecular Biology from the University of Wisconsin.

CEO Compensation
  • Insufficient data for Bill to compare compensation growth.
  • Insufficient data for Bill to establish whether their remuneration is reasonable compared to companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Axcella Health management team in years:

2.5
Average Tenure
47.5
Average Age
  • The tenure for the Axcella Health management team is about average.
Management Team

Bill Hinshaw

TITLE
President
AGE
50
TENURE
1.1 yrs

David Berry

TITLE
Co-Founder & Director
AGE
41
TENURE
11.5 yrs

Tom Leggett

TITLE
Chief Financial Officer
AGE
42
TENURE
2.5 yrs

Tony Tramontin

TITLE
Chief Scientific Officer and Senior VP of Research & Development
AGE
51
TENURE
2.1 yrs

Greg Sieczkiewicz

TITLE
Vice President of Legal Affairs

Karen Lewis

TITLE
Senior Vice President of Human Resources
TENURE
0.3 yrs

Anders Gram

TITLE
Chief Production & Global Supply Chain Officer and Senior Vice President
AGE
59
TENURE
4.1 yrs

Larry Bell

TITLE
Global Head of Regulatory Affairs & Pharmacovigilance and Senior Vice President
TENURE
4.1 yrs

Iman Barilero

TITLE
Chief Regulatory Science
TENURE
2.5 yrs

Manu Chakravarthy

TITLE
Chief Medical Officer & Senior VP of Clinical Development
AGE
45
TENURE
1.8 yrs
Board of Directors Tenure

Average tenure and age of the Axcella Health board of directors in years:

3.4
Average Tenure
50
Average Age
  • The tenure for the Axcella Health board of directors is about average.
Board of Directors

David Epstein

TITLE
Chairman
AGE
57
TENURE
1.6 yrs

Bill Hinshaw

TITLE
President
AGE
50
TENURE
1.1 yrs

David Berry

TITLE
Co-Founder & Director
AGE
41
TENURE
8.4 yrs

Chip Baird

TITLE
Director
AGE
47
TENURE
1.1 yrs

Gary Pisano

TITLE
Director & Scientific Advisor
AGE
57
TENURE
7.8 yrs

Chris Viehbacher

TITLE
Director
AGE
58
TENURE
3.8 yrs

Greg Behar

TITLE
Director
AGE
50
TENURE
3.4 yrs

Cristina Rondinone

TITLE
Director
AGE
58
TENURE
1.1 yrs

Stephen Hoge

TITLE
Director
AGE
43
TENURE
5.2 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Axcella Health individual insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
11. Jul 19 Buy David Epstein Individual 08. Jul 19 10. Jul 19 5,796 $9.00 $47,743
03. Jul 19 Buy David Epstein Individual 01. Jul 19 03. Jul 19 4,556 $8.99 $39,916
01. Jul 19 Buy David Epstein Individual 27. Jun 19 28. Jun 19 5,500 $10.04 $55,131
27. Jun 19 Buy David Epstein Individual 26. Jun 19 26. Jun 19 14,500 $9.57 $138,765
15. May 19 Buy Flagship Pioneering Company 13. May 19 13. May 19 500,000 $20.00 $10,000,000
X
Management checks
We assess Axcella Health's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Axcella Health has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

AXLA News

Simply Wall St News

AXLA Company Info

Description

Axcella Health Inc., a biotechnology company, researches and develops novel multifactorial interventions to support health and address dysregulated metabolism in the United States. The company develops its products based on its AXA Development Platform. It offers AXA1665 for use in treating hepatic encephalopathy; AXA1125 and AXA1957 to treat non-alcoholic fatty liver disease; AXA2678 for use in treating immobilization-induced acute muscle atrophy; and AXA4010 to target multiple biological pathways. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was founded in 2008 and is based in Cambridge, Massachusetts.

Details
Name: Axcella Health Inc.
AXLA
Exchange: NasdaqGM
Founded: 2008
$177,393,861
23,008,283
Website: http://www.axcellahealth.com
Address: Axcella Health Inc.
840 Memorial Drive,
Cambridge,
Massachusetts, 02139,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM AXLA Common Stock Nasdaq Global Market US USD 09. May 2019
Number of employees
Current staff
Staff numbers
52
Axcella Health employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/07/20 01:04
End of day share price update: 2019/07/19 00:00
Last estimates confirmation: 2019/06/25
Last earnings filing: 2019/06/20
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.